Sanofi Pre-Tax Income 2010-2025 | SNY
Sanofi annual/quarterly pre-tax income history and growth rate from 2010 to 2025. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Sanofi pre-tax income for the quarter ending March 31, 2025 was $2.273B, a 55.46% increase year-over-year.
- Sanofi pre-tax income for the twelve months ending March 31, 2025 was $8.059B, a 22.7% increase year-over-year.
- Sanofi annual pre-tax income for 2024 was $7.248B, a 6.38% decline from 2023.
- Sanofi annual pre-tax income for 2023 was $7.742B, a 29.5% decline from 2022.
- Sanofi annual pre-tax income for 2022 was $10.981B, a 19.02% increase from 2021.
Sanofi Annual Pre-Tax Income
(Millions of US $) |
| 2024 |
$7,248 |
| 2023 |
$7,742 |
| 2022 |
$10,981 |
| 2021 |
$9,226 |
| 2020 |
$15,768 |
| 2019 |
$3,161 |
| 2018 |
$5,202 |
| 2017 |
$6,251 |
| 2016 |
$6,283 |
| 2015 |
$5,822 |
| 2014 |
$7,618 |
| 2013 |
$6,114 |
| 2012 |
$7,558 |
| 2011 |
$7,408 |
| 2010 |
$7,435 |
| 2009 |
$8,460 |
Sanofi Quarterly Pre-Tax Income
(Millions of US $) |
| 2025-03-31 |
$2,273 |
| 2024-12-31 |
$435 |
| 2024-09-30 |
$3,852 |
| 2024-06-30 |
$1,499 |
| 2024-03-31 |
$1,462 |
| 2023-12-31 |
$-142 |
| 2023-09-30 |
$3,304 |
| 2023-06-30 |
$1,943 |
| 2023-03-31 |
$2,636 |
| 2022-12-31 |
$4,244 |
| 2022-09-30 |
$2,692 |
| 2022-06-30 |
$1,442 |
| 2022-03-31 |
$2,602 |
| 2021-09-30 |
$3,487 |
| 2021-06-30 |
|
| 2021-03-31 |
$2,379 |
| 2020-09-30 |
$2,861 |
| 2020-03-31 |
$2,174 |
| 2019-09-30 |
$2,282 |
| 2019-03-31 |
$1,539 |
| 2018-03-31 |
$1,479 |
| 2017-12-31 |
$824 |
| 2017-09-30 |
$2,234 |
| 2017-06-30 |
$1,447 |
| 2017-03-31 |
$1,746 |
| 2016-12-31 |
$1,205 |
| 2016-09-30 |
$2,396 |
| 2016-06-30 |
$1,539 |
| 2016-03-31 |
$1,144 |
| 2015-09-30 |
$2,058 |
| 2015-06-30 |
$2,083 |
| 2014-06-30 |
$1,580 |
| 2013-06-30 |
$705 |
| 2012-06-30 |
$1,901 |
| 2012-03-31 |
$2,736 |
| 2011-12-31 |
$1,092 |
| 2011-09-30 |
$3,133 |
| 2011-06-30 |
$1,433 |
| 2011-03-31 |
$1,750 |
| 2010-12-31 |
$239 |
| 2010-09-30 |
$2,048 |
| 2010-06-30 |
$2,456 |
| 2010-03-31 |
$2,692 |
| 2009-12-31 |
$2,266 |
| 2009-09-30 |
$2,410 |
| 2009-06-30 |
$1,615 |
| 2009-03-31 |
$2,169 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.078B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
